medigraphic.com
Revista Médica Sinergia

2019, Number 10

<< Back Next >>

Revista Médica Sinergia 2019; 4 (10)

Use of sodium glucose cotransporter- 2 inhibitors as an adjuvant insulin treatment in type 1 diabetic patients

Monge MLF, Muñoz LJP

Language: Spanish
References: 17
Page: 281
PDF size: 134.90 Kb.


ABSTRACT

In Type 1 Diabetes Mellitus, intensive insulin therapy is the first line of treatment. Sodium glucose-2 cotransporter inhibitors are drugs with a noninsulin mechanism of action that have been studied in these patients as the first oral medication for the disease. A review of original studies that analyzed the role of these drugs plus insulin was performed for the management of type 1 diabetes mellitus in adults, with the purpose of determining their efficacy and safety. The results of this review included a stable decrease in glycated hemoglobin A, weight loss and a decrease in the daily dose of insulin, with an increase in the incidence of diabetic ketoacidosis.


REFERENCES

  1. American Diabetes Association. 5. Lifestyle Management: Standards of Medical Care in Diabetes 2019. Diabetes Care. enero de 2019;42(Supplement 1):S46-60.https://doi.org/10.2337/dc19-S005

  2. Akturk HK, Rewers A, Garg SK. SGLT inhibition. Current Opinion in Endocrinology & Diabetes and Obesity. 2018 08;25(4):246-250. https://doi.org/10.1097/med.0000000000000423

  3. Actualización en diabetes tipo 1. En Madrid: Academia Española de Pediatría[Internet] 2019[Consultado 20 Jul 2019] p. 445-451. Disponible en: https://www.aepap.org/sites/default/files/pags._445- 452_actualizacion_en_diabetes.pdf

  4. Fattah H, Vallon V. The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus. Drugs. 2018;78(7):717-726.https://doi.org/10.1007/s40265-018-0901-y

  5. Sanofi / Lexicon Pharmaceuticals. Sotagliflozin as an Adjunct to Insulin for Type 1 Diabetes Endocrinologic and Metabolic Drugs Advisory Committee [Internet]. 2019. CO-1 – AA-15 Disponible en: https://www.fda.gov/media/121288/download

  6. Maddipatla M, Mathias T. FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes [Internet]. Reuters United States; Disponible en: https://www.reuters.com/article/us-sanofi-fr-fda/fda-rejects-sanofi-lexiconadd- on-pill-for-type-1-diabetes-idUSKCN1R32DM

  7. European Medicines Agency. First oral add-on treatment to insulin for treatment of certain patients with type 1 diabetes [Internet]. 2019. Disponible en: https://www.ema.europa.eu/en/news/first-oral-addtreatment- insulin-treatment-certain-patients-type-1-diabetes

  8. Kalra S. Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology. Diabetes Ther. diciembre de 2014;5(2):355-366. https://doi.org/10.1007/s13300-014-0089-4

  9. Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPAREG OUTCOME Trial. Circulation. el 12 de marzo de 2019;139(11):1384-1395. https://doi.org/10.1161/CIRCULATIONAHA.118.037778

  10. Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, Fagan NM, Kaspers S, Woerle H, Broedl UC, Johansen O. Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial. Diabetes Care. 2014 03 04;37(5):1480-1483. https://doi.org/10.2337/dc13-2338

  11. Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, et al. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. julio de 2015;38(7):1181-1188. https://doi.org/10.2337/dc14-2806

  12. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes. Diabetes Care. diciembre de 2015;38(12):2258-2265. https://doi.org/10.2337/dc15-1730

  13. Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, et al. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2017 Nov;5(11):864-876. https://doi.org/10.1016/s2213-8587(17)30308-x

  14. Buse JB, Garg SK, Rosenstock J, Bailey TS, Banks P, Bode BW, Danne T, Kushner JA, Lane WS, Lapuerta P, McGuire DK, Peters AL, Reed J, Sawhney S, Strumph P. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. Diabetes Care. 2018 06 24;41(9):1970-1980. https://doi.org/10.2337/dc18-0343

  15. Yang Y, Yang Y, Pan H, Wang B, Chen S, Zhu H, Pan H, Wang B, Chen S, Zhu H. Efficacy and Safety of SGLT2 Inhibitors in Patients with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials. Chinese Medical Sciences Journal. 2017;32(1):22 27. https://doi.org/10.24920/j1001- 9242.2007.003

  16. El Masri D, Ghosh S, Jaber LA. Safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 1 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice. 2018 03;137:83-92. https://doi.org/10.1016/j.diabres.2018.01.004

  17. Riddle MC, Cefalu WT. SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True? Diabetes Care. diciembre de 2018;41(12):2444-2447.https://doi.org/10.2337/dci18-0041




2020     |     www.medigraphic.com